Routine RSU scheme administration — no trading signal. Monitor for any future RSU grants or changes in the pace of trustee purchases that could signal insider sentiment or dilution trends.
Price Chart
Executive Summary
Ascentage Pharma's trustee purchased 200,000 existing shares (0.05% of issued shares) on-market for HK$5.78 million (~HK$28.89/share) to satisfy RSU vesting under the 2022 RSU Scheme. This is a routine administrative step to fund equity awards, not a buyback or capital return signal.
Key Facts
- Trustee purchased 200,000 existing shares on October 15, 2026 for the 2022 RSU Scheme
- Total consideration: HK$5,778,916 (approx. HK$28.89 per share)
- Purchased shares represent approximately 0.05% of total issued shares
- Trustee now holds 2,915,000 shares under the scheme
- Trustee does not exercise voting rights on shares held
- No new RSU grants were made — only purchases to satisfy existing awards
Financial Impact
HK$5.78 million spent on share purchases for RSU vesting — immaterial relative to market cap
Risk Factors
- No material risk identified from this routine filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-109623 |
| Document: ea0308726-6k_ascentage.htm | 0001213900-26-109623 |
| Document: 0001213900-26-109623-index-headers.html | 0001213900-26-109623 |
| Document: 0001213900-26-109623-index.html | 0001213900-26-109623 |
| Document: 0001213900-26-109623.txt | 0001213900-26-109623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.85 (−3.82%) |
Oct 21, 2026 6d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.85 (−0.47%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.85 (+1.09%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.85 (+3.38%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.85 (+14.26%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.85 (−11.90%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.85 (−11.63%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.85 (−21.39%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.85 (−19.16%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.85 (−22.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers